We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Hamilton Thorne Inc | TSXV:HTL | TSX Venture | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 1.45 | 1.40 | 1.48 | 0 | 00:00:00 |
From Feb 2020 to Feb 2025
"Hamilton Thorne's second quarter sales increased 14% over the prior year, and 27% over the first quarter, as we experienced growth across all of our product lines. Sales were bolstered by a strong market adoption of our newly introduced LYKOS™ laser system, while our Stiletto™ laser continues to open up new and exciting research areas in the stem cell field," said Meg Spencer, Chief Executive Officer of Hamilton Thorne Ltd. "The first half of 2011 brought the launch of several exciting products for our Company, and as we move into the second half of the year, we are excited to unveil additional products that will help our customers to discover and develop life-saving treatments for patients."
Second Quarter Highlights
Financial Results
All amounts are in US dollars, unless specified otherwise, and results expressed in accordance with the International Financial Reporting Standards ("IFRS"), which replaces Canadian Generally Accepted Accounting Policies ("GAAP") effective January 1, 2010 for all publicly accountable enterprises in Canada.
For the three months ended June 30, 2011, the Company reported a total sales increase of 14% to $1,833,242 for the quarter, an increase of $224,722 from $1,608,520 during the previous year, and an increase of 27% over the first quarter of 2011. Six months sales for 2011 of $3,278,655 were up 18%, from sales of $2,789,207 in 2010. This increase was attributable to increased demand for our existing products and improved budget availability for capital equipment purchases across all customer types and geographic regions. The Company's customers in the regenerative medicine field primarily use the Company's products in research applications.
Gross profit for the quarter increased 16% to $1,172,842 in the quarter ended June 30, 2011, compared to $1,009,321 in the previous year and increased to $2,053,372 versus $1,719,522 for the comparable six month periods. Gross profit as a percentage of sales were slightly higher at 64.0% for the quarter and 62.6% for the six months ended June 30, 2011, versus 62.7% and 61.6% for the comparable periods in 2010, due primarily to product mix and increased sales spread over a relatively constant overhead base.
Operating expenses were $1,460,591 and 2,960,476 for the quarter and six-months ended June 30, 2011, up from $1,332,421 and $2,543,293 for comparable periods during the previous year. This increase in operating expenses represents continued strategic investment in the growth of the Company.
Research and development expenses increased from $228,947 to $320,281 for the quarter ended June 30, 2012 and from $479,254 to $619,728 for the six-month period due to continued development of new products. Sales and marketing expenses increased from $595,107 to $675,063 for the quarter ended June 30, 2012 and from $1,080,794 to $1,309,240 for the six-month period due to the expansion of our sales and marketing staff, commission expense on higher sales volume, and increased variable costs of selling.
General and administrative (G&A) expenses decreased from $508,367 to $465,247. for the quarter ended June 30, 2011 versus the prior quarter and increased from $983,245 to $1,031,508 for the six-month period due primarily to increases in staffing, as well as foreign currency valuation adjustments related to the convertible debentures issued in August 2010 and March 2011 issued in Canadian dollars.
Net interest expense increased from $62,165 to $155,489 for the quarter ended June 30, 2011 and from $132,114 to $282,510 for the six-month period. The increase was due primarily to the non-cash interest expense, both coupon and accreted, on the Company's convertible debentures.
The net loss for the quarter ended June 30, 2011 increased from $385,265 to $443,328 and from $955,885 to $1,189,614 for the six-month period of the previous year. The increased loss was due primarily to the additional investments by the Company in research, product development, sales and marketing, additional general and administrative expenses and interest expense, partially offset by increased gross profit resulting from increased sales.
As of June 30, 2011, the Company had 24,415,157 common shares. As of June 30, 2011, there were 5,694,440 warrants outstanding to purchase common shares: 5,500,005, at a price of Cdn $0.60 which originally were set to expire in April 2011 but were extended by eighteen months to October 2012; and 194,435 warrants to acquire one common share at an exercise price of Cdn$0.50, expiring in August 2012 and March 2013, issued to its financial advisors in connection with the August 2010 and March 2011 sales of the convertible debentures.
Stock options issued to employees and directors outstanding at June 30, 2011 totaled 4,071,480 at exercise prices ranging from Cdn $0.205 to Cdn $0.7712. Options for 2,357,351 shares are exercisable as of June 30, 2011. Options expire at varying times from July 2012 through January 2021.
The financial statements are available on www.sedar.com.
About Hamilton Thorne Ltd. (www.hamiltonthorne.com)
Hamilton Thorne provides novel solutions for Life Science that reduce cost, increase productivity as much as ten-fold, and enable research breakthroughs in regenerative medicine, stem cell research and fertility markets. The Company's new LYKOS™, Staccato™ and Stiletto™ laser systems offer significant scientific advantages in the fields of developmental biology, cancer research and advanced cell biology. Hamilton Thorne's laser products attach to standard inverted microscopes and operate as robotic micro-surgeons, enabling a wide array of scientific applications and procedures. Each member of Hamilton Thorne's family of products serves a different research purpose. By simply turning the microscope turret, researchers can have a new world of scientific capabilities at their fingertips.
Hamilton Thorne's growing customer base includes pharmaceutical companies, biotechnology companies, fertility clinics, university research centers, and other commercial and academic research establishments worldwide. Current customers include world-leading research labs such as Harvard University, MIT, Yale, McGill University, DuPont, Monsanto, Charles River Labs, Jackson Labs, Merck, Novartis, Pfizer, Oxford University, and Cambridge.
Neither the Toronto Venture Exchange, nor its regulation services provider (as that term is defined in the policies of the exchange), accepts responsibility for the adequacy or accuracy of this release.
Certain information in this press release may contain forward-looking statements. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict. Actual results might differ materially from results suggested in any forward-looking statements. The Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements unless and until required by securities laws applicable to the Company. Additional information identifying risks and uncertainties is contained in filings by the Company with the Canadian securities regulators, which filings are available at www.sedar.com.
Hot Features
Premium
Hamilton Thorne Ltd.
Consolidated Statements of Financial Position
For the periods ended June 30, 2011 and December 31, 2010
(Expressed in U.S. Dollars - unaudited)
June 30, 2011 December 31, 2010
Assets
Current
Cash and cash equivalents 229,705 714,498
Accounts receivable 986,633 971,406
Inventories 701,286 544,170
Prepaid expenses and other current
assets 99,648 58,241
------------------ ------------------
2,017,272 2,288,315
Property and equipment 195,606 134,662
Other assets 112,996 111,968
------------------ ------------------
Total assets 2,325,874 2,534,945
================== ==================
Liabilities
Current
Accounts payable and accrued
liabilities 1,617,071 1,412,831
Notes payable 107,910 104,460
Capital lease obligations, current 30,621 20,250
Deferred revenue 54,985 91,086
------------------ ------------------
Total current liabilities 1,810,587 1,628,627
Capital lease obligations, non-
current 60,989 37,295
Deferred revenue, long-term 79,486 79,486
Long-term debt 6,793,598 6,121,015
------------------ ------------------
Total liabilities 8,744,660 7,866,423
------------------ ------------------
Shareholders' Equity (Deficiency)
Common shares 24,345,752 24,345,752
Warrants 353,495 349,019
Contributed surplus 705,366 607,535
Accumulated deficit (31,823,399) (30,633,784)
------------------ ------------------
Total Shareholders' equity
(deficiency) (6,418,786) (5,331,478)
------------------ ------------------
Total Liabilities and shareholders'
equity (deficiency) 2,325,874 2,534,945
================== ==================
Hamilton Thorne Ltd.
Consolidated Statements of Operations and Comprehensive Loss
For the three and six months ended June 30, 2011 and 2010
(Expressed in U.S. Dollars - unaudited)
Three Months ended June 30 Six Months ended June 30
2011 2010 2011 2010
Sales 1,833,242 1,608,520 3,278,655 2,789,207
Cost of sales 660,400 599,199 1,225,283 1,069,685
------------ ------------ ----------- -----------
1,172,842 1,009,321 2,053,372 1,719,522
------------ ------------ ----------- -----------
Expenses
Research and
development 320,281 228,947 619,728 479,254
Sales and marketing 675,063 595,107 1,309,240 1,080,794
General and
administrative 465,247 508,367 1,031,508 983,245
------------ ------------ ----------- -----------
Total expenses 1,460,591 1,332,421 2,960,476 2,543,293
------------ ------------ ----------- -----------
Loss from operations (287,749) (323,100) (907,104) (823,771)
Other income (expense)
Interest expense, net,
including accretion (155,489) (62,165) (282,510) (132,114)
------------ ------------ ----------- -----------
Net loss and
comprehensive loss (443,238) (385,265) (1,189,614) (955,885)
============ ============ =========== ===========
Loss per share
Basic $ (0.02) $ (0.02) $ (0.05) $ (0.04)
Diluted $ (0.02) $ (0.02) $ (0.05) $ (0.04)
Weighted average number
of common shares
outstanding
Basic 24,415,157 24,415,157 24,415,157 24,415,157
Diluted 24,415,157 24,415,157 24,415,157 24,415,157
Hamilton Thorne Ltd
Consolidated Statements of Cash Flows
For the three and six months ended June 30, 2011 and 2010
(Expressed in U.S. Dollars - unaudited)
Three Months ended Six Months ended
June 30 June 30
2011 2010 2011 2010
Cash flows from operating
activities
Net loss for the year (443,238) (385,265) (1,189,614) (955,885)
Adjustments to reconcile net
loss to net cash used in
operating activities:
Depreciation and
amortization 14,460 16,164 28,920 31,191
Non-cash interest
expense/accretion 103,897 - 213,271 -
Share-based payments
expense 34,560 61,245 74,310 122,490
Changes in non-cash
operating assets and
liabilities:
Accounts receivable (277,422) (502,981) (15,227) (585,072)
Inventories (79,302) (57,891) (157,116) (57,582)
Prepaid expenses and
other assets (52,200) 12,921 (41,407) 43,475
Other assets 557 - (1,028) (57,000)
Accounts payable and
accrued liabilities 117,014 342,087 116,705 324,455
Deferred revenue (22,067) 127,971 (36,101) 130,888
----------- ----------- ----------- -----------
Net cash flows used in
operating activities (603,741) (385,749) (1,007,287) (1,003,040)
----------- ----------- ----------- -----------
Cash flows from investing
activities
Purchase of capital assets (22,814) (11,101) (43,254) (48,197)
----------- ----------- ----------- -----------
Cash flows from financing
activities
Proceeds from debt 25,585 256,411 600,475 754,454
Costs of private placement
refunded 3,814 - 3,814
Payments on debt (16,564) (553,015) (34,727) (1,056,699)
----------- ----------- ----------- -----------
Net cash flows provided by
(used in) financing
activities 9,021 (292,790) 565,748 (298,431)
----------- ----------- ----------- -----------
Net Increase (decrease) in
cash and cash equivalents (617,534) (689,640) (484,793) (1,349,668)
Cash and cash equivalents,
beginning of period 847,239 696,343 714,498 1,356,371
Cash and cash equivalents,
end of period 229,705 6,703 229,705 6,703
=========== =========== =========== ===========
Supplemental disclosure of
cash flow information:
Cash paid during the period
for:
Interest 70,942 53,058 132,277 107,466
Supplemental disclosure of
non-cash financing
activities:
Equipment acquired under
capital lease 21,436 0 46,619 0
Add to Digg Bookmark with del.icio.us Add to Newsvine
For more information, please contact: David Wolf President Hamilton Thorne Ltd. 978-921-2050 Email Contact Lisa Rivero Director of Corporate Communications Hamilton Thorne Ltd. 978-921-2050 Email Contact
1 Year Hamilton Thorne Chart |
1 Month Hamilton Thorne Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
